Nyrada AGM 2021 Chairman’s Address
“Looking forward, we expect Phase I studies for both the Cholesterol-Lowering and Brain Injury Programs will commence in the second… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: • Cholesterol-Lowering Program advances: – New data from in vivo cholesterol study showed NYX-PCSK9i significantly increased plasma PCSK9 levels,… Read more
Nyrada Inc (ASX: NYR) Presentation to ASX Small and Mid-Cap Conference
Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be… Read more
Nyrada Inc (ASX:NYR) Full Year Results FY21
Highlights: • Research and development costs of $2.2M as Nyrada’s lead preclinical programs advance (FY2020: $1.4M) • Capital raising program… Read more
NYR In Vivo Trial Results Show Further Positive Results
Last Friday, Nyrada released further positive results from an animal trial using a mouse model genetically modified to mimic human-like… Read more
Nyrada Inc US Patent
This morning Nyrada announced the granting of a new patent by the US Patent and Trademark Office for their PCSk9i… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Confirmation of Capital Structure – CHESS Depositary Interests on Issue
Nyrada’s NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction in Preclinical Study
Nyrada Inc have this morning announced encouraging results from an invivo study of their PCSK9i cholesterol inhibitor combined with Pfizer’s… Read more